1. Liposomes Loaded with Everolimus and Coated with Hyaluronic Acid: A Promising Approach for Lung Fibrosis.
- Author
-
Pandolfi L, Marengo A, Japiassu KB, Frangipane V, Tsapis N, Bincoletto V, Codullo V, Bozzini S, Morosini M, Lettieri S, Vertui V, Piloni D, Arpicco S, Fattal E, and Meloni F
- Subjects
- Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Bronchoalveolar Lavage methods, Cell Cycle Checkpoints drug effects, Cells, Cultured, Drug Delivery Systems methods, Everolimus chemistry, Fibroblasts drug effects, Fibroblasts metabolism, Humans, Hyaluronan Receptors metabolism, Hyaluronic Acid chemistry, Inflammation drug therapy, Inflammation metabolism, Lung drug effects, Lung metabolism, Lung Diseases, Interstitial drug therapy, Lung Diseases, Interstitial metabolism, Macrophages, Alveolar drug effects, Macrophages, Alveolar metabolism, Polyethylene Glycols chemistry, Pulmonary Fibrosis metabolism, Everolimus pharmacology, Hyaluronic Acid pharmacology, Liposomes chemistry, Pulmonary Fibrosis drug therapy
- Abstract
Chronic lung allograft dysfunction (CLAD) and interstitial lung disease associated with collagen tissue diseases (CTD-ILD) are two end-stage lung disorders in which different chronic triggers induce activation of myo-/fibroblasts (LFs). Everolimus, an mTOR inhibitor, can be adopted as a potential strategy for CLAD and CTD-ILD, however it exerts important side effects. This study aims to exploit nanomedicine to reduce everolimus side effects encapsulating it inside liposomes targeted against LFs, expressing a high rate of CD44. PEGylated liposomes were modified with high molecular weight hyaluronic acid and loaded with everolimus (PEG-LIP(ev)-HA400kDa). Liposomes were tested by in vitro experiments using LFs derived from broncholveolar lavage (BAL) of patients affected by CLAD and CTD-ILD, and on alveolar macrophages (AM) and lymphocytes isolated, respectively, from BAL and peripheral blood. PEG-LIP-HA400kDa demonstrated to be specific for LFs, but not for CD44-negative cells, and after loading everolimus, PEG-LIP(ev)-HA400kDa were able to arrest cell cycle arrest and to decrease phospho-mTOR level. PEG-LIP(ev)-HA400kDa showed anti-inflammatory effect on immune cells. This study opens the possibility to use everolimus in lung fibrotic diseases, demonstrating that our lipids-based vehicles can vehicle everolimus inside cells exerting the same drug molecular effect, not only in LFs, but also in immune cells.
- Published
- 2021
- Full Text
- View/download PDF